NCT06554899 CIFeR - A Clinician-led Intervention to Address Fear of Cancer Recurrence
| NCT ID | NCT06554899 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Aarhus University Hospital |
| Condition | Fear of Cancer Recurrence |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2024-06-14 |
| Primary Completion | 2025-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 300 participants in total. It began in 2024-06-14 with a primary completion date of 2025-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The investigators will test a novel Clinician-led Intervention to address Fear of cancer Recurrence in cancer survivors (CIFeR), by 1) adapting the original Australian intervention manual to the Danish oncology context (CIFeR-DK), and 2) developing a brief e-learning program to train oncologists. The investigators will then 3) compare CIFeR-DK with an active control condition in a cluster-randomized controlled trial with 24 oncologists (the cluster unit) treating a minimum of 300 patients with breast, ovarian, lung and prostate cancer at Danish Oncology Departments at four hospitals in Aarhus, Vejle, Aalborg, and Copenhagen, and 4) explore fidelity, acceptability, feasibility, and perceived barriers and facilitators to use the intervention in routine follow-up care.
Eligibility Criteria
Inclusion Criteria: * Are ≥ 18 years old * Have completed their primary treatment, i.e., surgery, adjuvant chemotherapy, and/or radiotherapy, for breast, ovarian, prostate, or lung cancer at the participating departments between three weeks and three months previously. * Score \>= 13 on the FCRI-SF Exclusion Criteria: \-
Contact & Investigator
Robert Zachariae, Professsor
PRINCIPAL INVESTIGATOR
Aarhus University and Aarhus University Hospital, Denmark
Frequently Asked Questions
Who can join the NCT06554899 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Fear of Cancer Recurrence. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06554899 currently recruiting?
Yes, NCT06554899 is actively recruiting participants. Contact the research team at enissen@oncology.au.dk for enrollment information.
Where is the NCT06554899 trial being conducted?
This trial is being conducted at Aarhus, Denmark.
Who is sponsoring the NCT06554899 clinical trial?
NCT06554899 is sponsored by Aarhus University Hospital. The principal investigator is Robert Zachariae, Professsor at Aarhus University and Aarhus University Hospital, Denmark. The trial plans to enroll 300 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.